INTRODUCTION
============

Colorectal cancer (CRC) is a major public health problem, being the third most commonly diagnosed cancer and the fourth cause of cancer death worldwide.[@B1] In Korea, CRC was predicted to be the third leading cause of cancer death in 2017.[@B2] Although the survival rate of CRC has improved gradually, owing to early screening programs, new surgical techniques, and the development of more-effective systemic therapies, most patients with metastatic or recurrent CRC face death, with a median survival time of 30 months.[@B3] To develop future treatment strategies and prolong the survival of CRC patients, it is crucial to identify the molecular characteristics of CRC, either genomic or epigenomic.

CpG island methylator phenotype (CIMP) is a distinct subtype of various cancers, characterized by an increased frequency of aberrant promoter hypermethylation at specific loci. In cancers with CIMP, aberrant methylation of cytosine nucleotides within these CpG islands can lead to silencing of tumorsuppressor genes, which in turn promotes cancer development. CIMP is reproducibly observed in approximately 15% of CRC cases, and the subgroup defined as CIMP is characterized with high rates of *KRAS* or *BRAF* mutation.[@B4][@B5][@B6] A recent meta-analysis showed that CRC patients with CIMP have a worse prognosis than those without CIMP.[@B7] The CIMP subtype is more enriched in the right side colon when compared with the left side colon, thereby conferring a prognostic impact on CRC.[@B7][@B8]

Aberrant activation of the Wnt signaling pathway is one of the first events in CRC carcinogenesis. Genomic and epigenomic abnormalities in genes regulating the Wnt pathway, such as *APC* and *AXIN2*, are observed in most CRC patients. A decrease in the inhibitory proteins of the Wnt pathway can promote the proliferation and metastasis of CRC, and may be a determinant of a patient\'s prognosis. *DKK 1-3*, *WNT5A*, and *AXIN2* are negative regulators of the Wnt pathway, and they are frequently repressed by promotor methylation in CRC.[@B9][@B10] *AXIN2*, one of the genes that predicts high recurrence of surgically resected CRC, is derived from cancer stem cells and has been incorporated into methylation signatures.[@B11] A German group reported that hypermethylation of *TFAP2E* results in downregulation of *DKK4* and is a predictor of chemotherapy resistance in CRC.[@B12] CRC with loss of *WNT5A* expression and hypermethylation of *WNT5A* was reported to be associated with a poor prognosis in a previous study.[@B13]

The aim of this study was to evaluate the prognostic value of the methylation status of four Wnt pathway genes (*DKK3*, *WNT5A*, *AXIN2*, and *TFAP2E*) in metastatic or recurrent CRC patients. In addition, we explored the prognostic impact of the methylation status of an additional six genes from the classic CIMP panel.

MATERIALS AND METHODS
=====================

Study population
----------------

We included 236 patients with metastatic or recurrent CRC whose primary or metastatic tumor specimens were sufficient for evaluating methylation status by pyrosequencing. All patients were treated with first-line chemotherapeutics at Severance Hospital, Yonsei University from June 1999 to June 2010. Demographic and clinical information was obtained from the electronic medical records of Severance Hospital, and survival data were retrieved from the tumor registry at the Yonsei Cancer Center. Exclusion criteria comprised co-existing malignancies (except for non-melanoma skin cancer or *in situ* cervical cancer), cancer other than adenocarcinoma, and insufficient amount of formalin-fixed paraffin-embedded (FFPE) tumor tissue for DNA extraction. This study was approved by the Institutional Review Board (IRB) at Yonsei University Severance Hospital, Seoul, Korea (IRB Number 4-2013-0134).

Tumor mutation and methylation analysis
---------------------------------------

Genomic DNA from FFPE tissues was extracted using the QIAamp DNA FFPE tissue kit (Qiagen, Valencia, CA, USA). Extracted tumor DNA was used to evaluate the mutation status of *KRAS* at codons 12 and 13 and *BRAF* at codon 600 and the methylation status of six CpG islands from a classic CIMP panel (*MINT1*, *MINT2*, *MINT31*, *hMLH1*, *p16*, and *p14*) and four Wnt pathway-related genes (*DKK3*, *WNT5A*, *AXIN2*, and *TFAP2E*). The DNA was first treated with bisulfite, using an EZ Methylation kit (Zymo Research, Orange, CA, USA), and then pyrosequencing was performed using the PyroMark Q24 instrument (Qiagen). The detailed protocol for DNA mutation and methylation status evaluation using a pyrosequencer has been described in previous reports.[@B8][@B14] The methylation status of CpG island markers was based on a threshold value of 15% (negative, methylation level \<15%; positive, methylation level ≥15%). The numbers of CpGs analyzed in the pyrosequencing assay were 2 for *AXIN2*, *DKK3*, and *TFAP2E* and 3 for *WNT5A*. Given that the concordance in methylation between the adjacent CpGs was very high for all four genes, we used average methylation for our analysis. A CIMP-positive tumor was defined as one in which two or more CIMP markers were methylation positive. Patients were divided into three groups based on the methylation status of the 10 evaluated genes (group 1, 0 methylation; group 2, 1--2 methylations; group 3, 3 or more methylations).

Treatment and efficacy assessment
---------------------------------

All patients were treated with 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan as single agents or in combination. The dose and schedule of the FOLFOX and FOLFIRI regimens were the same as those described in other studies or guidelines. As a routine clinical protocol, tumor assessment for response to chemotherapy was evaluated every 8 to 12 weeks, using CT scanning or magnetic resonance imaging in accordance with the Response Evaluation Criteria in Solid Tumors (RECIST) ver. 1.1. Overall survival (OS) was calculated from the first day of diagnosis to the day of death or the last follow-up visit. Progression-free survival (PFS) was calculated from the first day of chemotherapy to the time of the first documentation of progression, death from any cause, or the date of last follow-up visit if no events had occurred. Objective response rate (ORR) was calculated as the proportion of complete response (CR) and partial response (PR) by RECIST criteria.

Statistical analysis
--------------------

Clinicopathologic variables were used as categorical variables. The difference in categorical variables and ORR was assessed by the chi-square or Fisher\'s exact test. Survival curves were estimated by the Kaplan-Meier method for OS and PFS, with 95% confidence interval (CI) for the median time to event. The log-rank test was used to compare the distribution of survival between groups in a univariate analysis. Multivariate analyses were carried out using the Cox proportional hazard regression model, including variables with *p*\<0.10 in the univariate analysis. Two-sided *p*-values of \<0.05 were considered to indicate statistical significance. All analyses were performed using SPSS for Windows, version 18.0 (SPSS Inc., Chicago, IL, USA).

RESULTS
=======

Baseline characteristics and genomic test
-----------------------------------------

A total of 194 patients had sufficient amounts of tumor DNA extract for methylation analysis ([Table 1](#T1){ref-type="table"}, [Supplementary Tables 1](#S1){ref-type="supplementary-material"} and [2](#S2){ref-type="supplementary-material"}, only online). Approximately two-thirds (n=127) of the patients were male, and half (n=107) had metastatic CRC at the time of initial diagnosis. The primary tumor was located in the right and left side of the colon in 22.2% (n=43) and 77.9% (n=151) of patients, respectively. Microsatellite instability (MSI) status was known in 140 patients, of which five were MSI-high. Based on the classic definition of CIMP, 59 (30.4%) patients were classified as CIMP positive. Genomic tests of *KRAS* and *BRAF* and the methylation status of Wnt genes are summarized in [Table 2](#T2){ref-type="table"}. Mutations in *KRAS* and *BRAF* were detected in 64 (33.0%) and 8 (4.1%) patients, respectively. CIMP-positive tumors harbored a significantly higher frequency of *KRAS* mutation than CIMP-negative tumors did (44.1% in CIMP+ vs. 28.1% in CIMP-; chi-square, *p*=0.03) ([Fig. 1](#F1){ref-type="fig"}). The frequency of BRAF mutation was also significantly higher in CIMP+ tumors (11.9% in CIMP+ vs. 0.7% in CIMP-; Fisher\'s exact test, *p*=0.01) ([Fig. 1](#F1){ref-type="fig"}). Based on methylation status, 38 (19.6%), 92 (47.4%), and 64 (33.0%) patients were divided into groups 1, 2, and 3, respectively. The mean number of methylations was higher in proximal-located CRC tumors (2.63, standard deviation 2.11) than in distal-located CRC tumors (1.91, standard deviation 1.72). The most frequently methylated marker in group 3 was p16 (85.9%; 55 of 64 patients).

Methylation status and response to chemotherapy
-----------------------------------------------

Among the 194 patients included, 167 received palliative first-line chemotherapy after diagnosis of metastatic or recurrent CRC. Surgical removal of metastatic lesions was amenable in 39 (23.4%) patients, and they were excluded from the ORR analysis. The 27 patients who did not receive palliative chemotherapy were excluded from both the ORR and survival analyses. More than two-thirds of the patients who received palliative first-line treatment were treated with either FOLFOX or FOLFIRI (n=114, 68.3%). The remaining patients were treated with either molecular targeted agents, such as bevacizumab or cetuximab (n=35, 20.9%), or single agents, such as 5-FU or Capecitabine (n=18, 10.8%). In 128 patients who did not undergo metastasectomy, ORR (CR+PR) was observed in 63 (49.2%), and 10 (7.8%) had only non-measurable lesions according to the RECIST criteria. The number of methylations in a CRC tumor sample was significantly associated with the ORR of first-line chemotherapy ([Fig. 2](#F2){ref-type="fig"}). The ORR was 66.7%, 46.3%, and 43.2% in group 1, 2, and 3, respectively. Only one (4.2%) patient experienced progressive disease (PD) in group 1, whereas nine (13.4%) had PD in groups 2 and 3.

Methylation status and survival
-------------------------------

With a median follow-up time of 38 months, 131 (67.5%) of the 194 patients died. However, we only selected the 167 patients who received first-line chemotherapy for our survival analysis. None of the 10 methylation sites was associated with OS in a univariate analysis. CIMP-positive patients exhibited a trend toward shortened survival, when compared with CIMP-negative patients (log-rank, *p*=0.16) ([Fig. 3A](#F3){ref-type="fig"}). Nevertheless, we found that a higher number of methylations was associated with shorter OS. The median OS was 39.1, 39.7, and 29.1 months in groups 1, 2, and 3, respectively (log-rank, *p*=0.013) ([Fig. 3B](#F3){ref-type="fig"}). In distal-located primary tumors, there was a statistically significant association between the number of methylations and the OS (n=132, median OS 39.1 months in group 1 vs. 43.0 months in group 2 vs. 31.2 months in group 3; *p*=0.011); however, this was not observed in proximal-located tumors (n=35, median OS 34.7 months in group 1 vs. 25.5 months in group 2 vs. 29.1 months in group 3; *p*=0.688).

Group 1 had statistically non-significant longer PFS of first-line chemotherapy than group 2 or 3 did. The median PFS was 9.2, 7.6, and 7.0 months in groups 1, 2, and 3, respectively (log-rank, *p*=0.198). In the 128 patients who did not undergo metastasectomy, the median PFS was 9.1, 6.4, and 6.7 months, respectively (log-rank, *p*=0.075). This trend toward improved survival in group 1 was also observed in the 39 patients who underwent metastasectomy: not reached, 49.6 months and 44.4 months in groups 1, 2, and 3, respectively (*p*=0.429).

Among the variables that were significantly associated with OS in the univariate analyses \[age, Eastern Cooperative Oncology Group performance status (ECOG PS), histologic grade, American Joint Committee on Cancer (AJCC) stage at diagnosis, BRAF mutation, resectability at the time of metastasis, objective response of chemotherapy\], the number of methylations was independently associated with decreased survival in all patients (OS for 0--2 methylations vs. ≥3 methylations; hazard ratio, 1.72, 95% CI, 1.16--2.56; *p*=0.007) ([Table 3](#T3){ref-type="table"}).

DISCUSSION
==========

In this study, we evaluated the methylation status of *DKK3*, *WNT5A*, *AXIN2*, and *TFAP2E* in patients with metastatic or recurrent CRC. Although a single methylation of one of the four genes was not associated with the prognosis of our subjects, higher numbers of methylations among the 10 evaluated genes was independently associated with poorer clinical outcome. In chemotherapy-treated CRC patients, OS was significantly longer in groups 1 and 2 than in group 3. In patients with measurable disease, the ORR was significantly higher in group 1 than in group 2 or 3, and the median PFS was numerically higher in group 1 than in group 2 or 3.

We selected four Wnt pathway genes and six classic CIMP panel genes because aberrant genomic or epigenomic changes of the Wnt signaling pathway are crucial in CRC carcinogenesis and progression. Methylation of *DKK3* was present in 53.1% of our patients, and was not associated with survival. Similarly, in a previous study by Yu, et al.,[@B15] *DKK3* methylation was detected in 67 of 128 (52.3%) patients with CRC tumors, and was not predictive of patient survival. However, they reported that *DKK3* methylation status may be of potential use as a prognostic marker in patients with gastric cancer who may benefit from aggressive treatment. Methylation of *WNT5A* has been detected in 18--54% of CRC tumors in previous studies.[@B8][@B16][@B17] *WNT5A* has been studied as an important functional and prognostic marker in various cancers. In CRC, Rawson, et al.[@B17] evaluated the largest cohort of 1232 patients, and showed that *WNT5A* was strongly associated with sporadic MSI-high tumors without prognostic implication, in concordance with the present study. These findings may indicate that the role of the Wnt signaling pathway varies between CRC subtypes, depending on the epigenetic event of related genes.

Methylation of *AXIN2* and *TFAP2E* was detected only in 5 (2.6%) and 4 (2.1%) patients, respectively, in the current study. Therefore, the number of patients was too small to analyze the prognostic impact of these genes. There are several possible reasons for why the frequency of methylation in both genes was lower than that reported in other western studies. First, the Asian ethnicity of our study population could have influenced the results. Yoon, et al.[@B18] reported that CRC from Asians have a lower rate of *BRAF* and *KRAS* mutations than that from people of African descent and Caucasians. Given that previous studies have reported that methylation of *AXIN2* and *TFAP2E* is correlated with *BRAF* mutation, the tumors in our study population may have intrinsically lower rates of methylation. Second, the study method used to detect CpG island methylation was different from that used in previous studies. Pyrosequencing is not as sensitive, but is specific, for detecting methylation status, compared to methylation-specific PCR, which has been utilized in many previous studies. However, some proportions of *AXIN2* and *TFAP2E* methylation could be false positives, given that miss-priming of methylation-specific PCR frequently occurs during experiments.[@B19] In addition, low tumor purity or tumor heterogeneity of biopsy specimens from metastatic CRC patients may have contributed to the low frequency of methylation: other studies examined the methylation status in operation specimens from early CRC patients.

Wnt pathway methylation is easy to assess in routine clinical practice, when compared with whole-genome or transcriptome analysis. In addition, the advantage of a DNA methylation marker is its stability and reproducibility, in contrast to RNA-based biomarkers, and actionability with demethylating agents, such as 5-Aza. Accordingly, recently, an international consortium attempted to share large-scale data and enable the classification of CRC into four consensus molecular subtypes (CMSs).[@B20] CMS4 subtype CRC patients exhibit worse prognosis than patients with other subtypes, and show low Wnt activity, which might have resulted from repression of Wnt pathway genes by CpG island methylation. Interestingly, De Sousa E Melo, et al.[@B11] documented that a stem cell-derived gene signature (mesenchymal features with chemotherapeutic resistance and high TGF-β signaling) was closely related to methylation-dependent tuning of the Wnt expression program.

The main limitations of our study are its retrospective nature and the heterogenous treatment protocols. Therefore, our results need to be validated in future prospective studies. Another study limitation is that we did not evaluate the extended RAS mutations (in exons 3 and 4 of *KRAS* and exons 2, 3, and 4 of *NRAS*) or the MSI status of all patients. However, this should not have a significant impact on our results because most of our patients did not receive anti-EGFR monoclonal antibody. Lastly, the absence of a consensus panel defining CIMP subgroups is a hurdle to be overcome with comparison with other future studies.

In conclusion, we found that a higher number of methylations among the 10 genes evaluated, comprising four Wnt pathway genes and six classic CIMP panel genes, was independently associated with poorer clinical outcomes in CRC patients. Further validation of these markers in prospective settings and early stage patients will guide CRC patients to more personalized treatment planning and, hopefully, improve clinical outcomes in the future.
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SUPPLEMENTARY MATERIALS
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###### Supplementary Table 1

Clinical Information according to CIMP Status

###### Supplementary Table 2

Clinical Information according to Methylation Status

![Distribution of mutations and methylation in our patients. Each bar represents individual mutations (light blue) and methylations (dark blue). CIMP is denoted by an orange bar. CIMP-positive tumors had more frequent *KRAS* or *BRAF* mutation than CIMP negative tumors. CIMP, CpG island methylator phenotype.](ymj-59-588-g001){#F1}

![Bar chart showing the best objective response of first-line chemotherapy in each group. ORR was higher in group 1 (66.7%) than in group 2 (46.3%) or 3 (43.2%). CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; UA, unavailable, ORR, objective response rate.](ymj-59-588-g002){#F2}

![Overall survival according to CpG island phenotype (A) and the number of methylations (B). CIMP, CpG island methylator phenotype.](ymj-59-588-g003){#F3}

###### Patient Characteristics

![](ymj-59-588-i001)

  Components                              Patients (n=194)
  --------------------------------------- ------------------
  Sex, n (%)                              
   Male                                   127 (65.5)
   Female                                 67 (34.5)
  Age (median, range)                     62 (22--94)
  ECOG PS, n (%)                          
   0                                      118 (60.8)
   1                                      76 (39.2)
  Histology, n (%)                        
   WD                                     9 (4.6)
   MD                                     151 (77.8)
   PD                                     12 (6.2)
   Mucinous or Signet ring cell           22 (11.3)
  Stage at the time of diagnosis, n (%)   
   Stage 2                                24 (12.4)
   Stage 3                                63 (32.5)
   Stage 4                                107 (55.2)
  Status at the study entry, n (%)        
   Metastatic                             106 (54.6)
   Recurrent                              78 (40.2)
   No recurrence                          10 (5.2)
  Primary tumor location, n (%)           
   Ascending                              38 (19.6)
   Transverse                             5 (2.6)
   Descending                             10 (5.2)
   Sigmoid                                50 (25.8)
   Rectum                                 91 (46.9)

ECOG PS, Eastern Cooperative Oncology Group performance status; WD, well differentiated; MD, moderately differentiated; PD, poorly differentiated.

###### Molecular Profile of Tumors

![](ymj-59-588-i002)

  Components                               Patients (n=194)
  ---------------------------------------- ------------------
  Microsatellite instability, n (%)        
   MSI-high                                5 (2.6)
   MSI-low                                 10 (5.2)
   MSS                                     125 (64.4)
   UA                                      54 (27.8)
  CpG island methylator phenotype, n (%)   
   CIMP+                                   59 (30.4)
   CIMP−                                   135 (69.6)
  Mutation status, n (%)                   
   *KRAS*                                  64 (33)
   *BRAF*                                  8 (4.1)
  Methylation, n (%)                       
   *p16*                                   93 (47.9)
   *p14*                                   21 (10.8)
   *MINT1*                                 41 (21.1)
   *MINT2*                                 31 (16)
   *MINT31*                                40 (20.6)
   *MLH1*                                  1 (0.5)
   *DKK3*                                  103 (53.1)
   *WNT5A*                                 62 (32)
   *AXIN2*                                 5 (2.6)
   *TFAP2E*                                4 (2.1)

UA, unavailable; MSI, microsatellite instability; MSS, microsatellite stable; CIMP, CpG island methylator phenotype.

###### Univariate and Multivariate Analyses for Overall Survival
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  Components                                   Univariate HR (95% CI)   *p* value   Multivariate HR (95% CI)   *p* value
  -------------------------------------------- ------------------------ ----------- -------------------------- -----------
  Age ≥65 vs. \<65                             1.25 (0.88--1.78)        0.21        1.78 (1.07--2.98)          0.027
  Male vs. Female                              0.92 (0.64--1.32)        0.64        \-                         
  WD/MD vs. PD^\*^/Mucin                       0.52 (0.34--0.80)        0.003       0.37 (0.22--0.61)          \<0.001
  ECOG PS 0 vs. 1                              1.39 (0.98--1.97)        0.068       0.70 (0.42--1.15)          0.158
  AJCC stage 2/3 vs. 4                         2.02 (1.41--2.89)        \<0.0001    2.50 (1.70--3.79)          \<0.001
  Proximal vs. Distal                          1.00 (0.92--1.10)        0.96        1.11 (0.68--1.83)          0.679
  *BRAF* mutation vs. wild type                2.38 (1.10--5.11)        0.027       1.36 (0.60--3.10           0.465
  Metastasectomy Y vs. N                       0.51 (0.31--0.83)        0.007       0.32 (0.13--0.80)          0.015
  Objective response CR/PR vs. SD/PD^†^        1.97 (1.35--2.87)        \<0.0001    1.83 (1.21--2.77)          0.004
  Bevacizumab/Cetuximab^‡^ used vs. not used   0.85 (0.61--1.17)        0.32        \-                         \-
  CIMP positive vs. negative                   1.30 (0.90--1.88)        0.16        \-                         
  *DKK3* methyl vs. unmethyl                   1.00 (0.71--1.41)        0.99        \-                         
  *WNT5A* methyl vs. unmethyl                  1.25 (0.87--1.78)        0.23        \-                         
  *AXIN2* methyl vs. unmethyl                  1.60 (0.65--3.93)        0.3         \-                         
  *TFAP2E* methyl vs. unmethyl                 1.89 (0.60--5.96)        0.28        \-                         
  Group 1/2 vs. 3                              1.37 (0.96--1.96)        0.082       1.72 (1.16--2.56)          0.007

ECOG PS, Eastern Cooperative Oncology Group performance status; WD, well differentiated; MD, moderately differentiated; PD^\*^, poorly differentiated; AJCC, American Joint Committee on Cancer; CR, complete response; PR, partial response; SD, stable disease; PD^†^, progressive disease; CIMP, CpG island methylator phenotype; group 1, no methylation; group 2, 1--2 methylation; group 3, 3 or more methylation; HR, hazard ratio; CI, confidence interval.

^‡^Bevacizumab was used in 22 patients and cetuximab was used in 16 patients.
